COMP <GO>
NNNN vs ABBV // FREE CASH FLOW YIELD
Anbio Biotechnology (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NNNN 4
— ABBV 8
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $3.36 (-9.68%) • MKT CAP: $535.3M
fcf-yield
-1.26%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 70.20% | +17.00 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | 29.00% | -12.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 33.3x | +58.20 | ABBV | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.26% | 3.47% | -4.73 | ABBV | /fcf-yield <GO> |
| Operating Margin | 66.70% | 24.60% | +42.10 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 8.60% | -3.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.9 | 65.1 | -27.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | 113.1x | -35.40 | NNNN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $513.86B | -$513.32B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | ABBV REV | NNNN GROSS % | ABBV GROSS % | NNNN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $61.16B | 87.2% | 70.2% | -$6.7M | $17.82B |
| FY 2024 | $8.2M | $56.33B | 71.9% | 70.0% | $2.1M | $17.83B |
| FY 2023 | $6.7M | $54.32B | — | — | $898.4K | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
ABBV // BETA 1.15